EU PV for Retapamulin-Prescribing

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

United States Pharmacovigilence Retapamulin-Prescribing

NCT01153880

Skin Infections, Bacterial

COMPLETED

Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus

NCT00539994

Infections, Bacterial

COMPLETED PHASE2

Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

NCT03124199

Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

COMPLETED PHASE3

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

NCT00719810

Skin Structure Infections Bacterial Skin Diseases Staphylococcal Skin Infections

COMPLETED PHASE2

Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

NCT03174184

Tuberculosis, Pulmonary

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Impetigo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

(1) Age <9 months

Age at time of prescription was \<9 months

Retapamulin

Intervention Type DRUG

Prescription for retapamulin

Co-prescription of retapamulin and topical mupirocin

Intervention Type DRUG

Same day prescriptions for retapamulin and topical mupirocin

Co-prescription of retapamulin and topical fusidic acid

Intervention Type DRUG

Same day prescription for retapamulin and fusidic acid.

(2) 9 months to 6 years

Age at time of prescription was 9 months to 6 years

Retapamulin

Intervention Type DRUG

Prescription for retapamulin

Co-prescription of retapamulin and topical mupirocin

Intervention Type DRUG

Same day prescriptions for retapamulin and topical mupirocin

Co-prescription of retapamulin and topical fusidic acid

Intervention Type DRUG

Same day prescription for retapamulin and fusidic acid.

(3) 7 years to 18 years

Age at time of prescription was 7 years to 18 years

Retapamulin

Intervention Type DRUG

Prescription for retapamulin

Co-prescription of retapamulin and topical mupirocin

Intervention Type DRUG

Same day prescriptions for retapamulin and topical mupirocin

Co-prescription of retapamulin and topical fusidic acid

Intervention Type DRUG

Same day prescription for retapamulin and fusidic acid.

(4) 19 to 65 years

Age at time of prescription was 19 to 65 years

Retapamulin

Intervention Type DRUG

Prescription for retapamulin

Co-prescription of retapamulin and topical mupirocin

Intervention Type DRUG

Same day prescriptions for retapamulin and topical mupirocin

Co-prescription of retapamulin and topical fusidic acid

Intervention Type DRUG

Same day prescription for retapamulin and fusidic acid.

(5) 66 years and older

Age at time of prescription was 66 years and older

Retapamulin

Intervention Type DRUG

Prescription for retapamulin

Co-prescription of retapamulin and topical mupirocin

Intervention Type DRUG

Same day prescriptions for retapamulin and topical mupirocin

Co-prescription of retapamulin and topical fusidic acid

Intervention Type DRUG

Same day prescription for retapamulin and fusidic acid.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Retapamulin

Prescription for retapamulin

Intervention Type DRUG

Co-prescription of retapamulin and topical mupirocin

Same day prescriptions for retapamulin and topical mupirocin

Intervention Type DRUG

Co-prescription of retapamulin and topical fusidic acid

Same day prescription for retapamulin and fusidic acid.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The study population will consist of all registered "research standard" patients on GPRD, as evaluated annually for five years. For each year of observation, the denominator of persons will be patients registered for at least one month during the prior calendar year. Hence, the five-year reporting period for distinct, non-overlapping, non-cumulative prescription use and will categorize persons by date of birth (mm/dd/year).